All content for touchPODCAST is the property of touchpodcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease
touchPODCAST
19 minutes 6 seconds
3 months ago
Focus on treatment advances for ATTRv: A heterogeneous, highly debilitating and ultimately fatal disease
touchEXPERT FOCUS for touchNEUROLOGY and touchCARDIO
Listen to Dr Chafic Karam share expert insights on diagnosing and managing ATTRv amyloidosis. In this short interview, he covers red-flag symptoms, diagnostic challenges and key strategies for differentiating ATTRv. He also discusses current treatment options, including TTR stabilisers and gene silencers, as well as emerging therapies aimed at improving patient outcomes.
The expert:
Dr Chafic Karam, University of Pennsylvania, Philadelphia, PA, USA
This touchPODCAST is for HCPs in the USA only.
This activity is funded by an independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our websites:
https://touchneurology.com/ and https://touchcardio.com/